Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion
-Top-line data anticipated in the first quarter of 2022-SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (Revelation),...